Biglycan variant polypeptides and methods of use
AssigneeTivorsan Pharmaceuticals, Inc.
InventorsJustin Fallon, Elizabeth John
Life of this patent
Estimating the term…
Abstract
The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include Amyotrophic Lateral Sclerosis (ALS), as well as muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.
Claims32
An isolated biglycan variant polypeptide lacking glycosaminoglycan side chains, wherein the variant polypeptide potentiates agrin-induced AChR clustering.
Dependencies are inferred from the claim text.